Rep. Norm Thurston — Voting Record

Utah House District 62 · complete roll-call record from le.utah.gov
← All votes

Bill

Veterans PTSD Clinical Research Amendments
Number
H.B. 390 (2026GS)
Sponsor
Rep. Dailey-Provost, Jennifer
Final action
Governor Signed 3/19/2026
Outcome
Became law — signed by Gov. Spencer J. Cox

Summary

This bill addresses psychedelic-assisted therapy for certain veterans.

What it does

  • This bill:
  • authorizes the Huntsman Mental Health Institute (Huntsman) to conduct a clinical study on the safety and feasibility of psychedelic-assisted therapy for veterans with treatment-resistant post-traumatic stress disorder;
  • permits Huntsman to accept donations to fund the clinical study;
  • requires Huntsman to begin the clinical study if legislative appropriations and donations combined are equal to or exceed an amount sufficient to begin the study;
  • requires reporting to the Health and Human Services Interim Committee;
  • provides a sunset date for the provisions related to the clinical study;
  • defines terms; and
  • makes technical and conforming changes.

Every vote on this bill

2026-02-09House Comm - Substitute Recommendation
House Health and Human Services Committee
10-0-4not eligible / no record
2026-02-09House Comm - Favorable Recommendation
House Health and Human Services Committee
10-0-4not eligible / no record
2026-02-24Senate Comm - Favorable Recommendation
Senate Health and Human Services Committee
5-0-2not eligible / no record
2026-02-26Senate/ circled
Senate 2nd Reading Calendar
0-0-29not eligible / no record
2026-02-26Senate/ uncircled
Senate 2nd Reading Calendar
0-0-29not eligible / no record
2026-02-26Senate/ passed 2nd reading
Senate 3rd Reading Calendar
29-0-0not eligible / no record
2026-03-04Senate/ passed 2nd & 3rd readings/ suspension
Senate President
27-0-2not eligible / no record
2026-02-18House/ passed 3rd reading
Senate Secretary
68-2-5YEA

Bill text

enrolled version · official source
11
26B-7-126
63I-1-226
0
Veterans PTSD Clinical Research Amendments
2026 GENERAL SESSION
STATE OF UTAH
Chief Sponsor: Jennifer Dailey-Provost
Senate Sponsor: Kirk A. Cullimore
Cosponsor:
Sahara Hayes
Carol S. Moss
Nelson T. Abbott
Sandra Hollins
Hoang Nguyen
John Arthur
Trevor Lee
Doug Owens
Jefferson S. Burton
Ashlee Matthews
Angela Romero
Rosalba Dominguez
Verona Mauga
Jake Sawyer
Jake Fitisemanu
Grant Amjad Miller
Andrew Stoddard
LONG TITLE
General Description:
This bill addresses psychedelic-assisted therapy for certain veterans.
Highlighted Provisions:
This bill:
authorizes the Huntsman Mental Health Institute (Huntsman) to conduct a clinical study 
on the safety and feasibility of psychedelic-assisted therapy for veterans with 
treatment-resistant post-traumatic stress disorder;
permits Huntsman to accept donations to fund the clinical study;
requires Huntsman to begin the clinical study if legislative appropriations and donations 
combined are equal to or exceed an amount sufficient to begin the study;
requires reporting to the Health and Human Services Interim Committee; 
provides a sunset date for the provisions related to the clinical study;
defines terms; and
makes technical and conforming changes.
Money Appropriated in this Bill:
None
Other Special Clauses:
None
Utah Code Sections Affected:
AMENDS:
63I-1-226
, as last amended by Laws of Utah 2025, Chapters 47, 277 and 366
ENACTS:
26B-7-126
, Utah Code Annotated 1953
Be it enacted by the Legislature of the state of Utah:
Section 1. Section 
26B-7-126
 is enacted to read:
26B-7-126
. Psychedelic-assisted therapy for veterans clinical study -- Funding -- 
Reports.
(1)
As used in this section:
(a)
"Clinical study" means the safety and feasibility study authorized in this section.
(b)
"Controlled substance" means the same as that term is defined in Section 
58-37-2
.
(c)
"Eligible veteran" means a veteran who has treatment-resistant PTSD.
(d)
"FDA" means the United States Food and Drug Administration.
(e)
"Huntsman Mental Health Institute" means the mental health and substance use 
treatment institute within the University of Utah.
(f)
"Investigational drug" means an investigational new drug that the FDA has 
authorized for human subjects research under 21 C.F.R. Part 312.
(g)
"Investigational new drug" means the same as that term is defined in 21 C.F.R. Sec. 
312.3.
(h)
"Psychedelic drug" means a controlled substance that is an investigational drug and 
has a hallucinogenic effect on the central nervous system, including:
(i)
3,4-Methylenedioxymethamphetamine (MDMA);
(ii)
5-methoxy-N,N-dimethyltryptamine; or
(iii)
Psilocybin.
(i)
"Psychedelic-assisted therapy" means an intervention where:
(i)
a psychedelic drug is administered to an individual with treatment-resistant PTSD 
in a controlled clinical setting; and
(ii)
a qualified therapist delivers manualized, trauma-informed preparatory and 
integrative psychotherapy to the individual before and after administration of the 
psychedelic drug.
(j)
"PTSD" means post-traumatic stress disorder.
(k)
"Treatment-resistant PTSD" means a clinical diagnosis of PTSD with documented 
inadequate response to one or more evidence-based treatments for PTSD.
(2)
Subject to Subsections 
(4)
 and 
(5)
, within appropriations from the Legislature for this 
purpose and any gifts, grants, or donations the Huntsman Mental Health Institute 
receives under Subsection 
(3)
, the Huntsman Mental Health Institute shall conduct a 
clinical study to research the safety and feasibility of psychedelic-assisted therapy for 
the treatment of treatment-resistant PTSD in eligible veterans.
(3)
The Huntsman Mental Health Institute may accept gifts, grants, and donations of money 
to fund the clinical study.
(4)
(a)
The Huntsman Mental Health Institute shall begin the clinical study no later than 
January 1, 2027, if the total amount of legislative appropriations and gifts, grants, or 
donations the Huntsman Mental Health Institute receives under Subsection 
(3)
reaches an amount that is equal to or exceeds an amount the Huntsman Mental Health 
Institute determines is sufficient to begin the clinical study.
(b)
If the Huntsman Mental Health Institute begins the clinical study on or before 
January 1, 2027, the Huntsman Mental Health Institute may:
(i)
accept gifts, grants, or donations after January 1, 2027; and
(ii)
use amounts received under Subsection 
(3)
, or appropriated by the Legislature for 
this purpose, after January 1, 2027, to continue funding the clinical study.
(5)
If the Huntsman Mental Health Institute does not begin the study on or before January 
1, 2027, because the total amounts accepted and appropriated under this section are 
insufficient to begin the clinical study, the Huntsman Mental Health Institute:
(a)
may continue to accept gifts, grants, or donations, after January 1, 2027;
(b)
shall begin the clinical study when the total amount of legislative appropriations and 
gifts, grants, or donations reaches an amount that is equal to or exceeds an amount 
the Huntsman Mental Health Institute determines is sufficient to begin the clinical 
study; and
(c)
may use amounts received under Subsection 
(3)
, or appropriated by the Legislature 
for this purpose, after January 1, 2027, to continue funding the clinical study.
(6)
The Huntsman Mental Health Institute shall return to a donor any unused gifts, grants, 
or donations the Huntsman Mental Health Institute received under Subsection 
(3)
 on or 
before July 1, 2032.
(7)
Before beginning the clinical study, the Huntsman Mental Health Institute shall:
(a)
comply with state and federal regulations, including by:
(i)
ensuring that the clinical study will be conducted under an FDA investigational 
new drug application;
(ii)
maintaining a United States Drug Enforcement Agency Schedule I research 
registration and any required state controlled substance registration; and
(iii)
obtaining Institutional Review Board approval for the clinical study;
(b)
have a clinical study protocol that includes:
(i)
the study design, inclusion and exclusion criteria, objectives and endpoints, 
eligible veteran visit schedule, and schedule of follow-up assessments;
(ii)
informed consent procedures and participant safeguards; and
(iii)
data security and privacy protections, including for personal information;
(c)
have a drug administration plan for the clinical study that includes:
(i)
the investigational drug product description, source, formulation, route of 
administration, and dosing regimen;
(ii)
a clinical staffing model and monitoring procedures for the administration of the 
investigational drug;
(iii)
discharge criteria and transportation procedures for participants after 
psychedelic-assisted therapy; and
(iv)
procedures for the storage, handling, chain of custody, and disposal of controlled 
substances, and an accountability plan for violations of the procedures;
(d)
have a safety monitoring and risk management plan for the clinical study that 
includes:
(i)
medical and psychiatric screening procedures;
(ii)
on-site emergency response procedures;
(iii)
adverse event and serious adverse event capture and reporting timelines; and
(iv)
predefined rules for pausing or stopping the clinical study; and
(e)
have a fidelity plan for the clinical study that includes:
(i)
a psychotherapy manual that describes preparatory sessions, therapeutic support 
boundaries for the administration of the investigational drug during 
psychedelic-assisted therapy sessions, and integrative sessions;
(ii)
therapist licensure and qualification requirements;
(iii)
a training, supervision, and fidelity monitoring plan; and
(iv)
ethical safeguards and a participant complaint and grievance process.
(8)
(a)
The Huntsman Mental Health Institute shall:
(i)
report to the Health and Human Services Interim Committee, upon request of the 
committee, on the progress of the clinical study; and
(ii)
submit a final written report of the clinical study to the Health and Human 
Services Interim Committee on or before the committee's first November meeting 
after the date on which the Huntsman Mental Health Institute concludes the 
clinical study.
(b)
The report described in Subsection 
(8)(a)(ii)
 shall include:
(i)
safety and feasibility outcomes for the use of psychedelic-assisted therapy for the 
treatment of treatment-resistant PTSD in eligible veterans; and
(ii)
secondary or exploratory clinical outcomes of the clinical study.
Section 2. Section 
63I-1-226
 is amended to read:
63I-1-226
. Repeal dates: Titles 26 through 26B.
(1)
Subsection 
26B-1-204(2)(g)
, regarding the Youth Electronic Cigarette, Marijuana, and 
Other Drug Prevention Committee, is repealed July 1, 2030.
(2)
Subsection 
26B-1-204(2)(h)
, regarding the Primary Care Grant Committee, is repealed 
July 1, 2035.
(3)
Section 
26B-1-315
, Medicaid ACA Fund, is repealed July 1, 2034.
(4)
Section 
26B-1-318
, Brain and Spinal Cord Injury Fund, is repealed July 1, 2029.
(5)
Section 
26B-1-402
, Rare Disease Advisory Council Grant Program -- Creation -- 
Reporting, is repealed July 1, 2026.
(6)
Section 
26B-1-409
, Utah Digital Health Service Commission -- Creation -- Membership 
-- Duties, is repealed July 1, 2025.
(7)
Section 
26B-1-410
, Primary Care Grant Committee, is repealed July 1, 2035.
(8)
Section 
26B-1-417
, Brain and Spinal Cord Injury Advisory Committee -- Membership 
-- Duties, is repealed July 1, 2029.
(9)
Section 
26B-1-422
, Early Childhood Utah Advisory Council -- Creation -- 
Compensation -- Duties, is repealed July 1, 2029.
(10)
Section 
26B-1-425
, Utah Health Workforce Advisory Council -- Creation and 
membership, is repealed July 1, 2027.
(11)
Section 
26B-1-428
, Youth Electronic Cigarette, Marijuana, and Other Drug Prevention 
Committee and Program -- Creation -- Membership -- Duties, is repealed July 1, 2030.
(12)
Section 
26B-1-430
, Coordinating Council for Persons with Disabilities -- Policy 
regarding services to individuals with disabilities -- Creation -- Membership -- 
Expenses, is repealed July 1, 2027.
(13)
Section 
26B-1-432
, Newborn Hearing Screening Committee, is repealed July 1, 2026.
(14)
Section 
26B-2-407
, Drinking water quality in child care centers, is repealed July 1, 
2027.
(15)
Subsection 
26B-3-107(9)
, regarding reimbursement for dental hygienists, is repealed 
July 1, 2028.
(16)
Section 
26B-3-136
, Children's Health Care Coverage Program, is repealed July 1, 2025.
(17)
Section 
26B-3-137
, Reimbursement for diabetes prevention program, is repealed June 
30, 2027.
(18)
Subsection 
26B-3-213(2)(b)
, regarding consultation with the Behavioral Health Crisis 
Response Committee, is repealed December 31, 2026.
(19)
Section 
26B-3-302
, DUR Board -- Creation and membership -- Expenses, is repealed 
July 1, 2027.
(20)
Section 
26B-3-303
, DUR Board -- Responsibilities, is repealed July 1, 2027.
(21)
Section 
26B-3-304
, Confidentiality of records, is repealed July 1, 2027.
(22)
Section 
26B-3-305
, Drug prior approval program, is repealed July 1, 2027.
(23)
Section 
26B-3-306
, Advisory committees, is repealed July 1, 2027.
(24)
Section 
26B-3-307
, Retrospective and prospective DUR, is repealed July 1, 2027.
(25)
Section 
26B-3-308
, Penalties, is repealed July 1, 2027.
(26)
Section 
26B-3-309
, Immunity, is repealed July 1, 2027.
(27)
Title 26B, Chapter 3, Part 5, Inpatient Hospital Assessment, is repealed July 1, 2034.
(28)
Title 26B, Chapter 3, Part 6, Medicaid Expansion Hospital Assessment, is repealed 
July 1, 2034.
(29)
Title 26B, Chapter 3, Part 7, Hospital Provider Assessment, is repealed July 1, 2028.
(30)
Section 
26B-3-910
, Alternative eligibility -- Report -- Alternative Eligibility 
Expendable Revenue Fund, is repealed July 1, 2028.
(31)
Section 
26B-4-710
, Rural residency training program, is repealed July 1, 2025.
(32)
Subsection 
26B-5-112(1)(b)
, regarding consultation with the Behavioral Health Crisis 
Response Committee, is repealed December 31, 2026.
(33)
Subsection 
26B-5-112(5)(b)
, regarding consultation with the Behavioral Health Crisis 
Response Committee, is repealed December 31, 2026.
(34)
Section 
26B-5-112.5
, Mobile Crisis Outreach Team Grant Program, is repealed 
December 31, 2026.
(35)
Section 
26B-5-114
, Behavioral Health Receiving Center Grant Program, is repealed 
December 31, 2026.
(36)
Section 
26B-5-118
, Collaborative care grant program, is repealed December 31, 2024.
(37)
Section 
26B-5-120
, Virtual crisis outreach team grant program, is repealed December 
31, 2026.
(38)
Subsection 
26B-5-609(1)(a)
, regarding the Behavioral Health Crisis Response 
Committee, is repealed December 31, 2026.
(39)
Subsection 
26B-5-609(3)(b)
, regarding the Behavioral Health Crisis Response 
Committee, is repealed December 31, 2026.
(40)
Subsection 
26B-5-610(1)(b)
, regarding the Behavioral Health Crisis Response 
Committee, is repealed December 31, 2026.
(41)
Subsection 
26B-5-610(2)(b)(ii)
, regarding the Behavioral Health Crisis Response 
Committee, is repealed December 31, 2026.
(42)
Section 
26B-5-612
, Integrated behavioral health care grant programs, is repealed 
December 31, 2025.
(43)
Title 26B, Chapter 5, Part 7, Utah Behavioral Health Commission, is repealed July 1, 
2029.
(44)
Subsection 
26B-5-704(2)(a)
, regarding the Behavioral Health Crisis Response 
Committee, is repealed December 31, 2026.
(45)
Title 26B, Chapter 5, Part 8,
 Utah Substance Use and Mental Health Advisory 
Committee, is repealed January 1, 2033.
(46)
Section 
26B-7-119
, Hepatitis C Outreach Pilot Program, is repealed July 1, 2028.
(47)
Section 
26B-7-122
, Communication Habits to reduce Adolescent Threats Pilot 
Program, is repealed July 1, 2029.
(48)
Section 
26B-7-123
, Report on CHAT campaign, is repealed July 1, 2029.
(49)
Section 
26B-7-126
, Psychedelic-assisted therapy for veterans clinical study -- Funding 
-- Reports, is repealed July 1, 2032.
(49)
(50)
Title 26B, Chapter 8, Part 5, Utah Health Data Authority, is repealed July 1, 
2026.
Section 3. 
Effective Date.
This bill takes effect on 
May 6, 2026
.
3-10-26 3:49 PM